Feiba Global Outcome Study (Feiba-Go): Long-Term Real World Data on Apcc (feiba(r) in Patients with Inhibitors. First Demographic Data

Introduction: Data on APCC´s effectiveness, safety and quality of life are relatively poor because of the rarity of patients with FVIII or FIX inhibitors, the small populations included in clinical trials and the relatively short follow-up available. The FEIBA-GO study was designed to capture long-term outcomes on effectiveness, safety and health-related quality of life (HR-QoL) in subjects receiving APCC in different settings in routine clinical practice.